##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/5378

Clinical reasoning: Pharmacovigilance report

Vol. 156 No. 8 (2026)

Extensive cervical myelitis following pembrolizumab treatment after prior radiotherapy: a case report

Cite this as:
Swiss Med Wkly. 2026;156:5378
Published
28.08.2026

Summary

INTRODUCTION: Immune checkpoint inhibitors represent a significant therapeutic advancement in the management of multiple malignancies. However, they are associated with rare but potentially severe neurological immune-related adverse events.

CASE PRESENTATION: We report the case of a patient in his 70s with metastatic lung adenocarcinoma who developed extensive cervical myelitis following pembrolizumab immunotherapy in the context of prior cervical radiotherapy. Spinal magnetic resonance imaging (MRI) revealed extensive inflammatory lesions involving the cervical spinal cord with extension to the thoracic region.

MANAGEMENT AND OUTCOMES: Despite the discontinuation of pembrolizumab and the early initiation of aggressive immunosuppressive therapy including high-dose corticosteroids, plasmapheresis, intravenous immunoglobulin and tocilizumab, the clinical course was rapidly and progressively unfavourable.

CONCLUSION: This case highlights the potential severity of immune-mediated myelitis, raises the question of whether there is a deleterious interaction between immune checkpoint inhibitor and prior radiotherapy, and illustrates the limitations of current therapeutic strategies in cases of refractory forms.

References

  1. 1. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016 Nov;12(11):2777–89. 10.1080/21645515.2016.1199310
  2. 2. Anderson D, Beecher G, Nathoo N, Smylie M, McCombe JA, Walker J, et al. Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. Neurooncol Pract. 2019 Sep;6(5):340–5. 10.1093/nop/npy039
  3. 3. Charabi S, Engell-Noerregaard L, Nilsson AC, Stenör C. Longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab. Front Neurol. 2021 Apr;12:655283. 10.3389/fneur.2021.655283
  4. 4. Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies. Front Neurol. 2022 Sep;13:1003270. 10.3389/fneur.2022.1003270
  5. 5. Chatterton S, Xi S, Jia JX, Krause M, Long GV, Atkinson V, et al. Case series: immune checkpoint inhibitor-induced transverse myelitis. Front Neurol. 2023 Feb;14:1130313. 10.3389/fneur.2023.1130313
  6. 6. Payá PR, Abad ÁM, Mirete BG, Arias AF, Rivilla MB, Benítez Fuentes JD, et al. Successful management of immune-mediated myelitis in a renal cancer patient: a case report. Case Rep Oncol. 2025 Jun;18(1):892–9. 10.1159/000543929
  7. 7. Piętak M, Kruczyk B, Domański P, Jarosińska J, Hołdakowska A, Demkow T, et al. Longitudinally extensive transverse myelitis after pembrolizumab and lenvatinib therapy for a rare subtype of renal cell carcinoma: A case report. Oncol Lett. 2025 Jun;30(2):386. 10.3892/ol.2025.15132
  8. 8. Owen T, Fung AS. Combination intravenous immune globulin (IVIG) and high-dose steroids for treatment of immune-related myelitis in a non-small cell lung cancer patient treated with pembrolizumab and palliative radiation : a case report. Clin Lung Cancer. 2022 Dec;23(8):e563–7. 10.1016/j.cllc.2022.08.012
  9. 9. Vickers ML, Seidl B, Bigby K, Chern B, Eriksson L, Hartnett G, et al. Inflammatory myeloradiculitis secondary to pembrolizumab: a case report and literature review. Case Rep Oncol Med. 2020 Aug;2020:8819296. 10.1155/2020/8819296
  10. 10. Hill AB. The Environment and Disease: association or Causation? Proc R Soc Med. 1965 May;58(5):295–300. 10.1177/003591576505800503
  11. 11. Carausu M, Beddok A, Langer A, Girard N, Bidard FC, Massiani MA, et al. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. J Immunother Cancer. 2019 Nov;7(1):317. 10.1186/s40425-019-0803-x
  12. 12. Chang VA, Simpson DR, Daniels GA, Piccioni DE. Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. J Immunother Cancer. 2018 Dec;6(1):153. 10.1186/s40425-018-0471-2
  13. 13. Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 1995 Mar;31(5):1093–112. 10.1016/0360-3016(94)00655-5
  14. 14. Picca A, Valyraki N, Birzu C, Kramkimel N, Hermine O, Zahr N, et al. Anti–interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021 Sep;8(6):e1073. 10.1212/NXI.0000000000001073
  15. 15. Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024 Dec;332(22):1924–35. 10.1001/jama.2024.19462